|1.||Lefebvre, Patrick: 14 articles (01/2012 - 11/2005)|
|2.||Henry, David H: 11 articles (02/2007 - 01/2004)|
|3.||Duh, Mei Sheng: 10 articles (07/2008 - 08/2005)|
|4.||Williams, Denise: 10 articles (12/2007 - 06/2005)|
|5.||Casadevall, Nicole: 9 articles (03/2015 - 05/2004)|
|6.||Mody, Samir H: 9 articles (09/2007 - 12/2004)|
|7.||Piech, Catherine Tak: 8 articles (05/2008 - 09/2005)|
|8.||McKenzie, R Scott: 8 articles (09/2007 - 09/2005)|
|9.||Wolfson, Marsha: 7 articles (04/2012 - 11/2006)|
|10.||Tomita, Dianne: 6 articles (11/2012 - 07/2003)|
04/01/1993 - "For most patients, therapy with Epoetin alfa reverses anemia and provides them with many benefits, including an improved quality of life. "
08/01/2003 - "Epoetin alfa has proven efficacy and safety in correcting anemia and improving QOL based on numerous clinical studies and over a decade of clinical practice. "
04/01/1992 - "Epoetin alfa therapy has been proven effective in treating anemia in dialysis patients; it increases the hematocrit (HCT) and improves the quality of life. "
02/01/2006 - "Early treatment with epoetin alfa to correct anemia improved QOL in a statistically significant and clinically meaningful way, and improvements were greater in patients with baseline Hb levels >10.5 g/dl."
06/01/2004 - "Once-weekly epoetin alfa therapy is safe and effective for treating anemia in patients with CKD not on dialysis, and is associated with significant improvements in functional status and quality of life."
01/01/2005 - "This confirmed that QoL is correlated with haemoglobin levels and that treatment with epoetin alfa is associated with a significant improvement in QoL as measured by validated cancer-specific instruments such as FACT and CLAS. "
01/01/2004 - "These findings support the use of epoetin alfa to achieve gains in QOL and cancer treatment outcomes in anemic cancer patients and suggest that additional studies be conducted to further investigate the potential benefits of this agent in regard to improved outcomes."
01/01/2005 - "Treatment with epoetin alfa has repeatedly been shown to improve the quality of life (QoL) of cancer patients with anaemia. "
09/01/2001 - "Improvement in quality of life for cancer patients treated with epoetin alfa."
12/01/2011 - "Thus, this study was designed to compare the prescribing of epoetin alfa at National Cancer Centre Singapore before and after FDA black box updates. "
|3.||Kidney Diseases (Kidney Disease)
01/01/2005 - "Eprex was administered intravenously to chronic kidney disease patients and, with improved storage and handling, there was a subsequent dramatic reduction in the number of cases. "
07/01/2008 - "Emerging evidence suggests that epoetin alfa can be administered at extended intervals of up to 4 wk. This open-label, randomized study was performed to characterize the pharmacokinetic and pharmacodynamic profiles of four dosing regimens of epoetin alfa administered subcutaneously in anemic patients who had chronic kidney disease and were not on dialysis. "
05/01/2007 - "The study patients had chronic kidney disease but were not receiving dialysis, had stable Hb levels of >or= 11.0 g/dL, and had been receiving epoetin alfa for >or= 2 months. "
08/01/2004 - "To evaluate the utility of a large-scale anti-EPO antibody screening program in patients with chronic kidney disease (CKD) administered epoetin alfa, a study involving 5 large renal centers in southern Ontario, Canada, was conducted. "
01/01/2013 - "Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease."
|4.||Chronic Kidney Failure (Chronic Renal Failure)
02/01/1996 - "Epoetin alfa therapy has dramatically improved therapeutic responses and outcomes for anemic patients with end-stage renal disease. "
04/01/1998 - "Since this program's inception, advances in technology (e.g., better dialysis equipment) and pharmacology (e.g., maintenance of an optimum hematocrit with Epoetin alfa) have greatly improved the care of patients with ESRD and increased the potential for successful rehabilitation. "
01/01/2004 - "Anaemia correction in patients with end-stage renal disease has been enhanced following the use of epoetin alfa or beta and there are a number of studies detailing its application. "
01/01/2004 - "A study of the response of elderly patients with end-stage renal disease to epoetin alfa or beta."
03/01/1990 - "In studies to date, both subjective and objective data show that epoetin alfa therapy significantly improves the quality of life of patients with ESRD."
|5.||Breast Neoplasms (Breast Cancer)
07/01/2009 - "Leyland-Jones et al. conducted a study evaluating the effects of early intervention with epoetin alfa (40,000 units administered subcutaneously every week) on survival and QOL of mainly nonanemic patients with metastatic breast cancer. "
10/01/2004 - "The findings of the study demonstrate for the first time in patients with breast cancer that epoetin alfa significantly enhances functional well-being, which translates into significantly better utility scores. "
09/01/2004 - "Although the study was not designed or powered for survival as an endpoint, Kaplan-Meier estimates for the full cohort showed a trend in overall survival favoring epoetin alfa treatment (P = 0.13, log rank test); a similar benefit was seen in the breast cancer subpopulation. "
10/01/2003 - "It appears that epoetin alfa is a useful addition to the treatment of breast cancer."
01/01/2003 - "To determine the incremental cost utility of epoetin-alfa versus placebo in anaemic patients with stage IV breast cancer from a UK National Health Service perspective. "
|3.||darbepoetin alfa (Aranesp)
|4.||Epoetin Alfa (Epogen)
|10.||Intercellular Signaling Peptides and Proteins (Growth Factors)
|1.||Drug Therapy (Chemotherapy)
|2.||Blood Transfusion (Blood Transfusions)
|4.||Renal Dialysis (Hemodialysis)